CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, December 6

Published: Dec. 2, 2021 at 4:30 PM EST

SEATTLE, Dec. 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at 3:40 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details: 
Event: JMP Securities Hematology & Oncology Summit  
Date: Monday, December 6, 2021 
Time: 3:40 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp. 
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts: 
Argot Partners 
+212-600-1902 
cti@argotpartners.com

(PRNewsfoto/CTI BioPharma Corp.)
(PRNewsfoto/CTI BioPharma Corp.)

View original content to download multimedia:

SOURCE CTI BioPharma Corp.

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.